A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with
recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101
is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with
belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.